Obesity and Energy Substrate Transporters in Ovarian Cancer-Review

Abstract

Ovarian cancer is the seventh most common cancer in women. It is characterized by a high mortality rate because of its aggressiveness and advanced stage at the time of diagnosis. It is a nonhomogenous group of neoplasms and, of which the molecular basics are still being investigated. Nowadays, the golden standard in the treatment is debulking cytoreductive surgery combined with platinum-based chemotherapy. We have presented the interactions and the resulting perspectives between fatty acid transporters, glucose transporters and ovarian cancer cells. Studies have shown the association between a lipid-rich environment and cancer progression, which suggests the use of correspondent transporter inhibitors as promising chemotherapeutic agents. This review summarizes preclinical and clinical studies highlighting the role of fatty acid transport proteins and glucose transporters in development, growth, metastasizing and its potential use in targeted therapies of ovarian cancer.

Keywords: cancer progression; lipids; obesity; ovarian cancer; targeted therapy.

Figure 1

High-grade ovarian cancer‚ omental cake-like metastasis to the omentum in a 68-year old female; FIGO IIIC; 2019. University Oncology Center, Bialystok, Poland.

Figure 2

Proposed model of FABP4 role in the ovarian cancer cell [75,78] by Baczewska et al. SU6656—SRC-inhibitor; L.D—lipid droplets; FFA—free fatty acids; HSL—hormone-sensitive lipase.